Related references
Note: Only part of the references are listed.Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy
N. Penel et al.
ANNALS OF ONCOLOGY (2013)
Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
Jean-Yves Blay et al.
BMC CANCER (2013)
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma
A. Gronchi et al.
ANNALS OF ONCOLOGY (2012)
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas
Axel Le Cesne et al.
EUROPEAN JOURNAL OF CANCER (2012)
A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials
Axel Le Cesne et al.
INVESTIGATIONAL NEW DRUGS (2012)
Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomas
Ruiz-Soto Rodrigo et al.
EUROPEAN JOURNAL OF CANCER (2011)
Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers
Roberta Sanfilippo et al.
GYNECOLOGIC ONCOLOGY (2011)
Activity of trabectidin in desmoplastic small round cell tumor
Ana Lopez-Gonzalez et al.
MEDICAL ONCOLOGY (2011)
Efficacy of trabectedin in metastatic solitary fibrous tumor
Loic Chaigneau et al.
RARE TUMORS (2011)
Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma
Javier Martinez-Trufero et al.
ANTI-CANCER DRUGS (2010)
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
MAPPING THE LITERATURE: ROLE OF TRABECTEDIN AS A NEW CHEMOTHERAPY OPTION IN ADVANCED PRETREATED SOFT TISSUE SARCOMA
A. Le Cesne et al.
DRUGS OF TODAY (2009)
Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma
Jean-Yves Blay et al.
CLINICAL CANCER RESEARCH (2008)
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
Federica Grosso et al.
LANCET ONCOLOGY (2007)
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: Multicenter phase II and pharmacokinetic study
R Garcia-Carbonero et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial
A Le Cesne et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy
R Garcia-Carbonero et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients
A Yovine et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
M Van Glabbeke et al.
EUROPEAN JOURNAL OF CANCER (2002)
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma:: a study by the EORTC Soft Tissue and Bone Sarcoma Group
I Judson et al.
EUROPEAN JOURNAL OF CANCER (2001)
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
OS Nielsen et al.
EUROPEAN JOURNAL OF CANCER (2000)
Share Paper
